Genocea Biosciences Statistics
Total Valuation
Genocea Biosciences has a market cap or net worth of 59.
| Market Cap | 59 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Genocea Biosciences has 58.78 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 58.78M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.02% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.02% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.35, with a Debt / Equity ratio of 1.25.
| Current Ratio | 1.35 |
| Quick Ratio | 1.12 |
| Debt / Equity | 1.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.30 |
| Interest Coverage | -52.70 |
Financial Efficiency
Return on equity (ROE) is -525.78% and return on invested capital (ROIC) is -143.44%.
| Return on Equity (ROE) | -525.78% |
| Return on Assets (ROA) | -57.59% |
| Return on Capital (ROIC) | -143.44% |
| Revenue Per Employee | 25,824 |
| Profits Per Employee | -502,581 |
| Employee Count | 74 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 27.45 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 46.31 |
| Average Volume (20 Days) | 4,332 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 19.57 |
Income Statement
In the last 12 months, Genocea Biosciences had revenue of 1.91 million and -37.19 million in losses. Loss per share was -0.53.
| Revenue | 1.91M |
| Gross Profit | 1.91M |
| Operating Income | -56.54M |
| Pretax Income | -37.19M |
| Net Income | -37.19M |
| EBITDA | -55.67M |
| EBIT | -56.54M |
| Loss Per Share | -0.53 |
Balance Sheet
The company has 20.14 million in cash and 15.49 million in debt, giving a net cash position of 4.65 million or 0.08 per share.
| Cash & Cash Equivalents | 20.14M |
| Total Debt | 15.49M |
| Net Cash | 4.65M |
| Net Cash Per Share | 0.08 |
| Equity (Book Value) | 12.39M |
| Book Value Per Share | 0.21 |
| Working Capital | 6.38M |
Cash Flow
In the last 12 months, operating cash flow was -48.19 million and capital expenditures -3.14 million, giving a free cash flow of -51.33 million.
| Operating Cash Flow | -48.19M |
| Capital Expenditures | -3.14M |
| Free Cash Flow | -51.33M |
| FCF Per Share | -0.87 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -2,958.87% |
| Pretax Margin | -1,946.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genocea Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.43% |
| Shareholder Yield | -29.43% |
| Earnings Yield | -63,035,593.22% |
| FCF Yield | -86,993,220.34% |
Stock Splits
The last stock split was on May 22, 2019. It was a reverse split with a ratio of 0.125.
| Last Split Date | May 22, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.125 |
Scores
Genocea Biosciences has an Altman Z-Score of -17.65. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.65 |
| Piotroski F-Score | n/a |